5 years ago NICE invited NWBO to submit but the company indicated it was not ready to do so. What it indicates is quite a bit of regulatory and medical interest in making DCVax-L available if possible.
I just posted a response to Senti’s much more informed post on the topic from 2017, and referencing a recent tweet that shows how many changes in NICE status were occurring in just the last few days of 2022. It’s really impossible to dismiss realistically as nothing, but I have no doubt people will try.
Market Data 
Markets 
AI
